Navigation Links
Mylan Reports That the FDA Determined That All Accusations Were Unfounded
Date:7/28/2009

PITTSBURGH, July 28 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today reported that in addition to the press release it issued on Sunday, the company proactively and as a courtesy had contacted the U.S. Food and Drug Administration (FDA) over the weekend to bring to its attention a recent news article. As a result, the FDA visited the company's Morgantown, W.Va., manufacturing facility Monday morning and has determined that the baseless accusations in the article were unfounded. The FDA noted there was no evidence of any data deletion. All data was reviewed and was present and accounted for; the Agency agreed that this was a minor Standard Operating Procedures (SOP) deviation that existed, was fully investigated, and all corrective actions were fully implemented by Mylan.

Mylan Chairman and CEO Robert J. Coury said: "I want to first thank the FDA for responding as quickly as it did in light of the seriousness of these unfounded accusations. I hope that these actions only reaffirm Mylan's long-standing reputation as one of the industry's highest quality manufacturers with a management team that has an unyielding commitment to adhere to the highest quality standards. I also want to thank all of the employees in Morgantown for their continued dedication, hard work and commitment to uphold one of the industry's highest quality standards. As far as the abnormal trading volume in our stock yesterday, the only thing I have to say is that there is no one in a better position to speak about these issues for a company than the standing fiduciaries, whether it is the senior management of the company or any regulatory agency. I would hope that the market and our stakeholders take note of this."

Mylan Inc., which provides products to customers in more than 140 countries and territories, ranks among the leading diversified generic and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest - and highest quality - product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's third largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies. For more information, please visit www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Mylan Reiterates and Stands Behind Its 48-Year Commitment and Track Record of Quality
2. Mylan Receives FDA Approval for Additional Strengths of the Antipsychotic Haloperidol
3. Mylan Declares Quarterly Preferred Stock Dividend
4. Mylan Receives FDA Approval for Generic Version of Thyroid Deficiency Treatment Cytomel(R)
5. Mylan Schedules Second Quarter 2009 Financial Results Conference Call and Live Webcast
6. Mylan Receives FDA Approval for Additional Strength of Generic Restoril(R)
7. Mylans Chief Operating Officer Heather Bresch to Testify Before Congress Concerning Patent Settlements Between Brand and Generic Pharmaceutical Companies and Tactics That Delay Market Entry of High Quality, Affordable Generic Drugs
8. Mylan Announces Successful Matrix Delisting Offer
9. Mylan Announces Change in Board Leadership
10. Mylan Receives Final FDA Approvals for Generic Versions of Anti-Rejection Medication CellCept(R)
11. Mylan Schedules First Quarter 2009 Financial Results Conference Call and Live Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... San Francisco, CA (PRWEB) , ... April 29, ... ... recently released fertility clinic data for 2014. Each year, reproductive endocrinologists are required ... CDC and SART, the main organization of professionals dedicated to the practice of ...
(Date:4/29/2016)... Los Angeles, California (PRWEB) , ... April 29, 2016 , ... ... all across USA, 1Heart Caregiver Services continues its successful franchise development and expansion as ... Ferdie has an extensive managerial and administrative experience in his 32 years of working ...
(Date:4/28/2016)... ... April 28, 2016 , ... The ... announced it has signed a letter of intent with Moda to ... Insurance Company (NORDIC). , Started by dentists 36 years ago, TDIC focuses exclusively ...
(Date:4/28/2016)... ... April 28, 2016 , ... CastCoverz!, America’s ... with AquaShieldUSA, the country's oldest waterproof cast protector . As the largest ... the largest selection of daily, night, weatherproof and waterproof covers for most orthopedic ...
(Date:4/28/2016)... (PRWEB) , ... April 28, 2016 , ... ... was among the organization’s most successful events, attracting medical professionals from around the ... and stimulating networking events. , Opening Ceremonies Sunday, April 17 included the introduction ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... 27, 2016 Transparency Market Research ... Market - Global Industry Analysis, Size, Share, Growth, Trends, ... the global skincare devices market was valued at US$ ... at a CAGR of 10.1% from 2015 to 2023 ... Browse the full Skincare Devices Market (Treatment Device - LED ...
(Date:4/27/2016)... 27, 2016  Bayer Animal Health today announced ... the University of Florida College of Veterinary Medicine, ... in Communication Award (BECA). Brittany was selected from ... a total of $70,000 in scholarship funds through ... Bayer has provided a total of $232,500 in ...
(Date:4/27/2016)... , April 27, 2016 ... ), a developer of a new generation of ... positive overall survival results for Paclical/Apealea in the ... 789 patients with epithelial ovarian cancer. These preliminary ... Paclical/Apealea in combination with carboplatin versus Taxol in ...
Breaking Medicine Technology: